Type 5 Diabetes: Cracking the Enigma

Needs Statement

To ensure accurate and effective patient care, healthcare providers in endocrinology require enhanced knowledge of core endocrine conditions, including the latest diagnostic and therapeutic approaches. There is a need to strengthen competence in applying evidence-based medicine and clinical guidelines, while also promoting high-value care and performance excellence across all disciplines within endocrinology. Additionally, providers must understand the scientific rigor behind guideline development and explore novel models of multidisciplinary care that foster collaboration and improve patient outcomes. This series aims to support these needs by offering regular updates on advances in basic science and clinical research, emerging treatment modalities, and evolving management strategies for endocrine disorders. By inviting expert speakers, the series delivers authoritative insights and practical strategies for improving clinical outcomes.

Educational Objectives

At the conclusion of the activity, the participants should be able to:

• Review the 70-year history that culminated in the naming of type 5 diabetes.
• Demonstrate greater understanding of the phenotype of type 5 diabetes using sophisticated metabolic measures.
• Differentiate type 5 diabetes from other diabetes phenotypes.

Target Audience

Activity Evaluation

Evaluation by questionnaire will address program content, presentation, and possible bias.

Educational Methods

• Lectures
• Case Presentations
• Literature Review
• Panel Discussion

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term of Approval

February 1, 2026 through February 29, 2028. Original release date: February 1, 2026.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.